Pumarix
Withdrawn
pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)
Medicine
Human
Withdrawn
On 11 February 2015, the European Commission withdrew the marketing authorisation for Pumarix (pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)) in the European Union (EU). The withdrawal was requested by the marketing authorisation holder, GlaxoSmithKline Biologicals, which notified the European Commission that it did not intend to maintain the marketing authorisation for commercial reasons.
Pumarix was granted a marketing authorisation in the EU on 4 March 2011 for prevention of influenza (flu) in an officially declared pandemic situation. The marketing authorisation was valid for a 5-year period, subject to subsequent renewals. Pumarix has never been marketed in the EU, and was intended to be used in an officially declared influenza pandemic following the identification and, if appropriate, the inclusion of the influenza strain causing the pandemic into the vaccine. Another product, Adjupanrix (pandemic influenza vaccine A/H5N1, split virion, inactivated, adjuvanted) is authorised in the EU for prevention of influenza in an officially declared pandemic situation, and can be used instead of Pumarix. The marketing authorisation holder, GlaxoSmithKline Biologicals, will maintain the marketing authorisation for Adjupanrix.
The European Public Assessment Report (EPAR) for Pumarix is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
Prophylaxis of influenza in an officially declared pandemic situation.
Pandemic-influenza vaccine should be used in accordance with official guidance.